Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue
NCT07915375, Not yet recruiting, Murdoch Childrens Research Institute
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Perceptions and Acceptance of Grafting of Cryopreserved Testicular Tissue | ClinicalTrials.gov |
| NCT number | NCT07915375 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 105 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Murdoch Childrens Research Institute | ClinicalTrials.gov |
| Conditions | Fertility, Testicular Tissue Cryopreserved, Fertility Preservation | ClinicalTrials.gov |
| Interventions | No intervention | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Willingness to consider testicular tissue grafting as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting as measured by the likert scale will range from 1 (strongly agree) to 7 (strongly disagree). Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Willingness to consider testicular tissue grafting within a specified time period (1 year) as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting as measured by the likert scale will range from 1 (strongly agree) to 7 (strongly disagree). Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Willingness to consider testicular tissue grafting within a specified time period (5 year) as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting as measured by the likert scale will range from 1 (strongly agree) to 7 (strongly disagree). Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Willingness to consider testicular tissue grafting within a specified time period (10 year) as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting as measured by the likert scale will range from 1 (strongly agree) to 7 (strongly disagree). Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Willingness to consider testicular tissue grafting according to perceived potential beneficial outcomes as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting in the hope that it will contribute to \[parenthood as soon as possible\] \[mature sperm that can be frozen\] \[improved guidelines for testicular grafting\]. Responses from 1 strongly agree to 7 strongly disagree. Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Willingness to consider testicular tissue grafting according to perceived safety as measured by responses to a likert scale on the study survey | Baseline | Willingness to undergo testicular tissue grafting because it is \[safe\] \[acceptable\] \[within my right to do so\] responses as percentages 0, 1, 5, 10, 20% or more. Responses from 1 strongly agree to 7 strongly disagree. Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing); or agree/disagree. | ClinicalTrials.gov |
| Secondary | Perceived social pressure from partners, parents, general practitioners (GP) and religious leaders as measured by responses to the Theory of Planned Behaviour questionnaire. | Baseline | Responses from 1 strongly agree to 7 strongly disagree. Responses will be assessed where 4 will be designated neutral. Survey responses will be dichotomised (\<4 = not willing and \>4 = willing) | ClinicalTrials.gov |
| Secondary | Perceived behavioural control as measured by responses to the Theory of Planned Behaviour questionnaire. | Baseline | Responses to either disagree or agree. | ClinicalTrials.gov |
| Secondary | Unmet fertility information needs as measured by The Unmet Needs Survey (per Benedict) | Baseline | Unmet fertility information needs is assessed on a 6-point scale, ranging from 0 to 5, higher scores indicate greater unmet information needs. Unmet fertility information needs will be summarised as a mean score. | ClinicalTrials.gov |
| Secondary | Decisional Conflict as measured by the Decisional Conflict Scale (DCS) | Baseline | The decisional conflict scale ranges between 0 to 100.Higher scores on the scale indicate greater decisional conflict. | ClinicalTrials.gov |
| Secondary | Cancer impact and information as measured by The Cancer Impact and Information Needs survey [per Adolescent and Young Adult Health Outcomes and Patient Experience (AYA HOPE)] | Baseline | Assess opportunity of making a decision measured by cancer impact and information needs. Cancer impact and information needs are assessed on a 6 point Likert scale (1 = Very negative impact and 6 = Does not apply). | ClinicalTrials.gov |
| Secondary | Financial toxicity survey as measured by the Comprehensive Score for Financial Toxicity (COST). | Baseline | Financial toxicity scale is evaluated using an 11 items survey where scores range from 0 to 44 with lower scores indicating a higher cancer-related financial impact. | ClinicalTrials.gov |
| Secondary | Anxiety as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) 6a | Baseline | PROMIS anxiety is assessed using their short form with 6 items (PROMIS 6a) items in a 5 Likert scale (1 = never and 5 = always) raw scores are transformed using PROMIS T-score tables, higher T score means worse health. | ClinicalTrials.gov |
| Secondary | Depression as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) 6a | Baseline | PROMIS depression is assessed using their short form with 6 items (PROMIS 6a) items in a 5 Likert scale (1 = never and 5 = always) raw scores are transformed using PROMIS T-score tables, higher T score means worse health. | ClinicalTrials.gov |
| Secondary | Stress as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) 8a | Baseline | PROMIS stress is assessed using its short form (PROMIS 8a) 8 items in a 5 Likert scale (1 = never and 5 = always) raw scores are transformed using PROMIS T-score tables, higher T score means worse health. | ClinicalTrials.gov |
| Secondary | Optimism as measured by the adapted Life Orientation Scale | Baseline | Optimism (Life Orientation) scale is used in the reduced form with only the optimistic measures (3-item Life Orientation Test-Revised (LOT-R) optimism subscale) with responses assessed in a 5-point Likert scale ranging from 1 = strongly disagree and 5 = strongly agree, higher scores indicate higher dispositional optimism. | ClinicalTrials.gov |
| Secondary | Medical Decision-Making preferences as measured by the Control Preferences Scale | Baseline | Medical Decision-Making preference is evaluated following the Control Preference Scale, where 5 items are ranked from the most preferred to the least preferred option, the highest rank item will determine if the chosen role is active, passive or collaborative. | ClinicalTrials.gov |
| Secondary | Reproductive Goals (per Lehmann [adapted]) | Baseline | Reproductive goals are assessed using 5 items categorising responses between yes, no or unsure. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 7
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)